Pros and cons of existing treatment modalities in osteoporosis: A comparison between tibolone, SERMs and estrogen (±progestogen) treatments

Journal of Steroid Biochemistry and Molecular Biology

Volumn 83, Issue 1-5, 2002, Pages 157-165

  Kloosterboer, H J ^a   Ederveen, A G H ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Bone; Estrogens; Osteoporosis; SERMs; STEARs; Tibolone

Indexed keywords

3 ALPHA HYDROXYTIBOLONE; 3 BETA HYDROXYTIBOLONE; 4 HYDROXYTAMOXIFEN; CONJUGATED ESTROGEN; DRUG METABOLITE; DYDROGESTERONE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; NORGESTREL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TIBOLONE; UNCLASSIFIED DRUG; PREGNANE DERIVATIVE;

BLEEDING; BONE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE REMODELING; BONE TURNOVER; BREAST; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ESTROGEN ACTIVITY; HUMAN; INCIDENCE; INHIBITION KINETICS; MENOPAUSAL SYNDROME; METABOLITE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; SIDE EFFECT; STIMULATION; THROMBOEMBOLISM; VEIN THROMBOSIS; VERTEBRA FRACTURE; CHEMICAL MODEL; ENDOMETRIUM; FEMALE; METABOLISM; POSTMENOPAUSE; REVIEW;

BONE AND BONES; ENDOMETRIUM; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; HUMANS; MODELS, CHEMICAL; NORPREGNENES; OSTEOPOROSIS; POSTMENOPAUSE; PROGESTINS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0037643399     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00055-4     Document Type: Conference Paper

References (79)

1. Greendale G.A., Lee N.P., Arriola E.R. The menopause. Lancet. 353:1999;571-579.
2. Ahlborg H.G., Johnell O., Nilsson B.E., Jeppson S., Rannevik G., Karlsson M.K. Bone loss in relation to menopause; a prospective study during 16 years. Bone. 28:2001;327-331.
3. Lindsay R., Silverman S.L., Cooper C., Hanley D., Barton J., Broy S.B., Licata A., Benhamou L., Geusens P., Flowers K., Stracke H., Seeman E. Risk of new vertebral fracture in the year following a fracture. J. Am. Med. Assoc. 285:2001;320-323.
4. Compston J.E. Sex steroid and bone. Physiol. Rev. 81:2001;419-447.
5. Rickard D.J., Waters K.M., Ruesink T.J., Koshla S., Katzenellenbogen J.A., Katzenellenbogen B.S., Riggs B.L., Spelsberg T.C. Estrogen receptor isoform-specific induction of progesterone receptors in human osteoblasts. J. Bone Miner. Res. 17:2002;580-592.
6. Waters K.M., Rickard D.J., Riggs B.L., Koshla S., Katzenellenbogen J.A., Katzenellenbogen B.S., Moore J., Spelsberg T.C. Estrogen regulation of human osteoblast function is determined by the stage of differentiation and the estrogen receptor isoform. J. Cell. Biochem. 83:2001;448-462.
7. Riggs B.L., Kohsla S., Melton L.J. III Sex steroid and the construction and conservation of the adult skeleton. Endo. Rev. 23:2002;279-302.
8. Villareal D.T., Binder E.F., Williams D.B., Schechttman K.B., Yarasheski K.E., Kohrt W.M. Bone mineral density response to estrogen replacement in frail elderly women. J. Am. Med. Assoc. 286:2001;815-820.
9. Lindsay R., Aitken J.M., Anderson J.B., Hart D.M., MacDonald E.B., Clarke A.C. Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet. II:1976;1038-1041.
10. Whitehead M.I., Townsend P.T., Pryse-Davies J., Path F.C.R., Ryder T.A., King R.J.B. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. New Engl. J. Med. 305:1981;1599-1605.
11. Writing Group for the Women's Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principle results from the Women's Health Initiative Randomized Controlled Trial, J. Am. Med. Assoc. 288 (2002) 321-333.
12. Schoonen W.G.E.J., Deckers G.H., de Gooyer M.E., de Ries R., Kloosterboer H.J. Hormonal properties of norethisterone, 7α-methyl-norethisterone and their derivatives. J. Steroid Biochem. Mol. Biol. 74:2000;213-222.
13. Prior J.C. Progesterone as a bone-trophic hormone. Endo. Rev. 1:1990;386-398.
14. Lindsay R., Hart D.McK., Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD14) for preventing postmenopausal osteoporosis. Br. Med. J. 280:1980;1207-1209.
15. Cosman F., Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endo. Rev. 20:1999;418-434.
16. Delmas P.D., Bjarnason M.H., Mitlak B.H., Ravouz A.C., Shah A., Huster W.J., Draper M., Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New Engl. J. Med. 337:1997;1641-1647.
17. Kloosterboer H.J. Tibolone: a steroid with a tissue-specific mode of action. J. Steroid Biochem. Mol. Biol. 76:2001;231-238.
18. Barkhem T., Carlsson B., Nilsson Y., Enmark E., Gustafsson J.-J., Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 54:1998;105-112.
19. Kuiper G.G.J.M., Carlsson B., Grandien K., Enmark E., Haeggblad J., Nilsson S., Gustafsson J.-J. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β Endocrinol. 138:1997;863-870.
20. de Gooyer M.E., Deckers G.H., Schoonen W.G.E.J., Verheul H.A.M., Kloosterboer H.J. Receptor profiling and endocrine interactions of tibolone. Steroids. 68:2002;21-30.
21. Sims N.A., Dupont S., Krust A., Clement-Lacroix P., Minet D., Resche-Rigon M., Gaillard-Kelly M., Baron R. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-B in bone remodeling in females but not in males. Bone. 30:2002;18-25.
22. Couse J.F., Korach K.S. Estrogen receptor null mice what have we learned and where will they lead us. Endo. Rev. 20:1999;358-417.
23. Li X., Takahashi M., Kushida K., Koyoma S., Hoshino H., Kawana K., Horuchi K., Inoue T. The effect of tamoxifen on bone metabolism and skeletal growth is different in ovariectomized and intact rats. Calif. Tissue Int. 59:1996;271-276.
24. Frolik C.A., Bryant H.U., Black E.C., Magee D.E., Chandrasekhar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen and alendronate. Bone. 18:1996;621-627.
25. Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:1997;753-758.
26. McDonnell D.P., Norris J.D. Connections and regulation of the human estrogen receptor. Science. 296:2002;1642-1644.
27. Evans G.L., Bryant H.U., Magee D.E., Turner R.T. Raloxifene inhibits bone turnover and prevents further cancallous bone loss in adult ovariectomized rats with established osteopenia. Endocrinol. 137:1996;4139-4144.
28. De Gooyer M.E., Overklift Vaupel Kleyn G.T., Smits K.C., Ederveen A.G.H., Verheul A.M., Kloosterboer H.J. Tibolone: a compound with tissue-specific inhibitory effects on sulfatase. Mol. Cell End. 183:2001;55-62.
29. M.E. de Gooyer, H.M. Oppers-Tiemissen, D. Leysen, H.A.M. Verheul, H.J. Kloosterboer, Tibolone is not converted by human aromatase to 7α-methyl-17α-ethynylestradiol (7α-MEE), analysis with sensitive bioassays for estrogens and androgens and LC-MSMS, Steroids 68 (2003) 233-241.
30. Tang B., Markiewicz L., Kloosterboer H.J., Gurpide E. Human endometrial 3β-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD14). J. Steroid Biochem. Mol. Biol. 45:1993;345-351.
31. Ederveen A.G.H., Kloosterboer H.J. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J. Bone Min. Res. 16:2001;1651-1657.
32. Anonymous, Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI). The Writing Group for the PEPI, J. Am. Med. Assoc. 276 (1996) 1389-1396.
33. Munk-Jensen N., Pors Nielsen S., Obel E.B., Bonne Eriksen P. Reversal of postmenopausal bone loss by oestrogen and progestogen: a double blind placebo controlled study. Br. Med. J. 296:1988;1150-1152.
34. Riis B.J., Johansen J., Christiansen C. Continuous oestrogen-progestogen treatment and bone metabolism in postmenopausal women. Maturitas. 10(1):1988;51-58.
35. Torgenson D.J., Bell-Syer S.E.M. Hormone replacement therapy and prevention of non-vertebral fractures. A meta-analysis of randomized trials. J. Am. Med. Assoc. 285:2001;2891-2897.
36. K. Michaelsson, J.A. Baron, O. Johnell, I. Persson, S. Ljunghall, Swedish Hip Fracture Study Group, Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture, Osteoporosis Int. 8 (1998) 540-546.
37. J. Cauley, D.G. Seeley, K. Ensrud, B. Ettinger, D. Black, S.R. Cummings, Study of Osteoporotic Fractures Research Group, Estrogen replacement therapy and fractures in older women, Ann. Intern. Med. 122 (1995) 9-16.
38. R. Marcus, M. Wong, H. Heath III, J.L. Stock, Antiresorptive treatment of postmenopausal osteoporosis; comparison of study designs and outcomes of large clinical trials with fractures as an endpoint, Endocrine Rev. 23 (2002) 16-37.
39. Ke H.Z., Chen H.K., Simmons H.A., Qi H., Crawford D.T., Pirie C.M., Chidsey-Frink K.L., Ma Y.F., Jee W.S.S., Thopson D.D. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone. 20:1997;31-39.
40. Turner C.H., Sato M., Bryant H.U. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinol. 135:1994;2001-2005.
41. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., Draper M., Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New Engl. J. Med. 337(23):1997;1641-1647.
42. Heaney R.H., Draper M.W. Raloxifene and estrogen; comparative bone-remodelling kinetics. J. Clin. Endocrinol. Metab. 82:1997;3425-3429.
43. P.D. Delmas, K.E. Ensrud, J.D. Adachi, K.D. Harper, S. Sarkar, C. Gennari, J.-Y. Reginster, H.A.P. Pols, R.R. Recker, S.T. Harris, W. Wu, H.K. Genant, D.M. Black, R. Eastell, MORE investigators, Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis four-year results from a randomized clinical trial, J. Clin. Endocrinol. Metab. 87 (2002) 3609-3617.
44. Ederveen A.G.H., Kloosterboer H.J. Tibolone, a steroid with tissue-specific hormone profile, completely prevents ovariectomy-induced bone loss in sexually mature rats. J. Bone Miner. Res. 14:1999;1963-1970.
45. Ederveen A.G.H., Spanjers C.P.M., Quaytaal J.H.M., Kloosterboer H.J. Effect of 16 months of treatment with tibolone on bone mass, turnover, and biomechanical quality in mature ovariectomized rats. J. Bone Miner. Res. 16:2001;1674-1681.
46. Clarkson T.B., Anthony M.S., Wagner J.D. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 86:2001;5396-5404.
47. Geusens P., Dequeker J., Gielen J., Schot L.P.C. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. Maturitas. 13:1991;151-159.
48. Berning B., van Kuijk C., Kuiper J.W., Coelingh Bennink H.J.T., Kicovic P.M., Fauser B.J.C.M. Effects two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a 2-year randomized, placebo-controlled study. Bone. 19:1996;395-399.
49. Gallagher J.C., Baylink D.J., Freeman R., McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, doses finding studies. J. Clin. Endocrinol. Metab. 869:2001;4717-4726.
50. Bjarnason N.H., Bjarnason K., Haarbo J., Christiansen C. Tibolone: prevention of postmenopausal bone loss in elderly women. J. Clin. Endocrinol. Metab. 81:1996;2419-2422.
51. Bjarnason N.H., Bjarnason K., Hassager C., Christiansen C. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone. 20:1997;151-155.
52. Rymer J., Robinson J., Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric. 5:2002;309-398.
53. B. Shea, G. Wells, A. Cranney, N. Zytarak, V. Robinson, L. Griffith, Z. Ortiz, J. Peterson, J. Adachi, P. Tugwell, G. Guyait, The Osteoporosis Methodology Group, The Osteoporosis Research Group, VII, Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis, Endo. Rev. 23 (2002) 552-559.
54. Lippuner K., Haenggi W., Birkhaueser M.H., Casez J.-P., Jaeger P. Prevention of postmenopausal bone loss usingtibolone or conventional peroral or transdermal hormone replacement therapy with 17β-estradiol and dydrogesterone. J. Bone Miner. Res. 12:1997;806-812.
55. Prelevic G.M., Bartram C., Wood J., Okolo S., Ginsburg J. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. Gynecol. Endocrinol. 10:1996;413-420.
56. Thiebaud D., Bigler J.M., Renteria S., Pache T., Welti H.J., Landry M., Burckhart P. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. Climacteric. 1:1998;202-210.
57. Roux C., Pelissier C., Fechtenbaum J., Loiseau-Peres S., Benhamou C.L. Randomized, double-masked, 2-year comparison of tibolone with 17β-estradiol and norethisterone acetate in preventing postmenopausal bone loss. Osteoporosis Int. 13:2002;241-248.
58. Delmas P.D., Confavreux E., Garnero P., Fardellone P., de Verne Joul M.-C., Cormier C., Arce J.-C. A combination of low doses of 17β-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteroporosis Int. 11:2000;177-187.
59. Landgren M.B., Coelingh Bennink H.J.T., Helmond F.A., Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. Br. J. Obstet. Gynaecol. 109:2002;1109-1114.
60. Moore R.A. Livial: a review of clinical studies. Br. J. Obstet. Gynaecol. 106:1999;1-21.
61. Morris E.P., Wilson P.O.G., Robinson J., Rymer J.M. Long term effects of tibolone on the genital tract in postmenopausal women. Br. J. Obstet. Gynaecol. 106:1999;954-959.
62. Laan E., van Lunsen R.H.W., Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric. 4:2001;28-41.
63. Voelker W., Coelingh Bennink H.J.T., Helmond F. Effects of tibolone on the endometrium. Climacteric. 4:2001;203-208.
64. White I.N. Anti-oestrogenic drugs and endometrials cancers. Toxicol. Lett. 120:2001;21-29.
65. H.J. Kloosterboer, New mechanism of action for tibolone in breast cancer, in: M. Neves-e-Castro, B.G. Wren (Eds.), Menopause, Hormones and Cancer, Parthenon, New York, 2002, pp. 37-47.
66. Huber J., Palacios S., Berglund L., Hänggi W., Sathanandan H., Christau S., Helmond F. The effect of tibolone compared with conjugated equine oestrogens continuously combined with medroxyprogesterone acetate on bleeding rates, quality of life and tolerability in postmenopausal women. Br. J. Obstet. Gynaecol. 109:2002;886-893.
67. Winkler U.H., Altkemper R., Kwee B., Helmond F.A., Coelingh Bennink H.J.T. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade; a multicenter, double blind, randomized study. Fertil. Steril. 74:2000;10-19.
68. Valdivia I., Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin. Drug Invest. 20:2000;101-107.
69. Lundström E., Christow A., Kersemaekers W., Svane G., Azavedo E., Soederqvist G., Mol-Arts M., Barkfeldt J., von Schoulz B. Effects of tibolone and continuous combined hormone replacement therapy on mamopraphic density. Am. J. Obstet. Gynecol. 186:2002;717-722.
70. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. J. Am. Med. Assoc. 19:1998;605-613.
71. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., Hisia J., Hulley S., Herd A., Khan S., Newby L.K., Waters D., Vitinghoff E., Wenger N. HERS Research Group, Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERSII). J. Am. Med. Assoc. 288:2002;49-57.
72. Cauley J.A., Norton L., Lippman M.E., Eckert S., Krueger K.A., Purdie D.W., Farrerons J., Kurasik A., Mellstrom D., Ng K.W., Stepan J.J., Powles T.J., Morrow M., Costa A., Silfen S.L., Walls E.L., Schmitt H., Muchmore D.B., Jordan V.C. Continued breast cancer risk reduction in postmenopausal women treated wit raloxifene: 4-year results from the MORE trial. Breast Cancer Res. Treat. 65:2001;125-134.
73. E. Barrett-Connor, Raloxifene: risks and benefits, Ann. New York Acad. Sci. 949 (2001).
74. D. Crook, Cardiovascular risk assessment for postmenopausal hormone replacement therapies such as tibolone (Livial), in: A.R. Genazzani (Ed.), Controversies in Cardiovascular Disease and Hormone Replacement Therapy, Parthenon, New York, 2000, pp. 1-8.
75. Jackson G. Tibolone and the cardiovascular system. Eur. Heart J. 3(Suppl. M):2001;M17-M21.
76. von Eckardstein A., Crook D., Elbers J., Ragoobir J., Ezeh B., Helmond F., Muller N., Dieplinger H., Coelingh Bennink H.J., Assmann G. Tibolone lowers high density lipoprotein cholesterol concentrations by increasing hepatic lipase activity but does not impair cholesterol efflux. Clin. Endocrinol. 58:2003;49-58.
77. F.A. Helmond, H.J. Kloosterboer, Safety and tolerability profile of Livial, in: A.R. Genazzani (Ed.), Hormone Replacement Therapy and Cancer: The Current Status of Research and Practice, Parthenon, New York, 2002, pp. 252-256.
78. Chetrite G.S., Pasqualini J.R. The selective estrogen enzyme modulator (SEEM) in breast cancer. J. Steroid Biochem. Mol. Biol. 76:2001;95-104.
79. Purdie D.W. What is tibolone and is it a SPEAR? Climacteric. 5:2002;236-239.